Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)

This publication has 17 references indexed in Scilit:

• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
  Published by Elsevier ,2005
• PPARγ and atherosclerosis
  Current Medical Research and Opinion, 2005
• Diabetes and cardiovascular risk markers
  Current Medical Research and Opinion, 2005
• Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
  JAMA, 2002
• Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels
  Circulation, 1998
• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
  New England Journal of Medicine, 1998
• Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels
  JAMA, 1998
• Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
  Diabetes Care, 1997
• Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study
  Diabetes Care, 1979